Global Alzheimer’s Disease Treatment Market US$ 13.2 Billion by 2023

The global Alzheimer’s disease treatment market to attain US$ 13.2 Billion by 2023, growing at a CAGR of 19.7% over the forecast period.

Visit Alzheimer’s disease treatment market by drug class (API) – acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine), immunoglobulin (gammagard liquid), N-methyl-daspartate (NMDA) receptor antagonist (memantine); by geography and forecast 2015-2023 at https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/

The global Alzheimer’s disease treatment market report provides market size (Revenue US$ Million 2015 to 2023), market share and forecasts growth trends (CAGR%, 2018 to 2023). The global Alzheimer’s disease market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The research report is divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global Alzheimer’s market include Abbott Laboratories, AC Immune, Affiris, AstraZeneca, Baxter International, Biogen Inc., Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen Pharmaceuticals (Johnson & Johnson), Lundbeck, Merck & Co., Neurim Pharmaceuticals, Novartis, Pfizer, Roche (Genentech), TauRx Therapeutics, vTv Therapeutics, and Warner-Lambert.

1. Drug Class (API)
1.1. Acetylcholinesterase (AChE) Inhibitors
1.1.1. Donepezil
1.1.2. Galantamine
1.1.3. Rivastigmine
1.2. Immunoglobulin
1.2.1. Gammagard Liquid
1.3. N-Methyl-Daspartate (NMDA) Receptor Antagonist
1.3.1. Memantine

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Abbott Laboratories
3.2. AC Immune
3.3. Affiris
3.4. AstraZeneca
3.5. Baxter International
3.6. Biogen Inc.
3.7. Bristol-Myers Squibb
3.8. Eisai
3.9. Eli Lilly
3.10. Janssen Pharmaceuticals (Johnson & Johnson)
3.11. Lundbeck
3.12. Merck & Co.
3.13. Neurim Pharmaceuticals
3.14. Novartis
3.15. Pfizer
3.16. Roche (Genentech)
3.17. TauRx Therapeutics
3.18. vTv Therapeutics
3.19. Warner-Lambert

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.